Silexion Therapeutics (NASDAQ:SLXN) Trading Down 0.4% – Here’s Why

by · The Cerbat Gem

Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) shares were down 0.4% during mid-day trading on Wednesday . The stock traded as low as $2.53 and last traded at $2.70. 92,192 shares changed hands during trading, a decline of 57% from the average daily volume of 212,417 shares. The stock had previously closed at $2.71.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold”.

View Our Latest Stock Analysis on SLXN

Silexion Therapeutics Price Performance

The stock has a fifty day moving average price of $5.36 and a two-hundred day moving average price of $13.93. The company has a market cap of $1.16 million, a P/E ratio of -0.03 and a beta of -0.32.

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($12.90) by $12.05. As a group, analysts forecast that Silexion Therapeutics Corp will post -45.5 earnings per share for the current year.

Silexion Therapeutics Company Profile

(Get Free Report)

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.

Recommended Stories